Coronavirus tally: Pfizer's Paxlovid COVID antiviral has little benefit for younger adults, new stud

Pfizer's COVID antiviral Paxlovid appears to have little or no benefit for younger adults, although it still reduces the risk of hospitalization or death in seniors, according to a new Israeli study, the Associated Press reported. Data from the 109,000 patient study may renew questions about the U.S. government's use of Paxlovid, which has become the go-to treatment for COVID-19 due to its at-home convenience. The Biden administration has spent more than $10 billion purchasing the drug and...